

DANIEL RICKLIN, PH.D. – PUBLICATION LIST (FEBRUARY 2025)

Total number of publications = 130, Total number of citations = 17765, h-index = 57 (PubMed, Google Scholar)
 A recent publication overview can be accessed at: <https://www.ncbi.nlm.nih.gov/pubmed/?term=ricklin-djau>

- Sommer-Plüss CJ, Leiggenger C, Nikci E, Mancuso RV, Rabbani S, Lamers C*, **Ricklin D***. 2025. Determining Ligand Binding and Specificity Within the $\beta 2$ -Integrin Family with a Novel Assay Platform, *Biomolecules* 15, 238.
- van Beek AE, Jeanguenat H, Häberli C, Pouw RB, Lamers C, Pál G, Gál P, Schmidt CQ, **Ricklin D***, Keiser J*. 2024. Praziquantel and factor H recruitment differentially affect the susceptibility of *Schistosoma mansoni* to complement-mediated damage. *Front. Immunol.* 15:1474358.
- Ricklin D.** 2024. Complement-targeted therapeutics: Are we there yet, or just getting started? *Eur. J. Immunol.* 54, e2350816.
- Kinzi J, Hussner J, Seibert I, Vythilingam M, Vonwyl C, Gherardi C, Detampel P, Schwardt O, **Ricklin D**, Meyer zu Schwabedissen HE. 2024. Impact of OATP2B1 on Pharmacokinetics of Atorvastatin Investigated in rSico2b1-Knockout and SLCO2B1-Knockin Rats. *Drug Metab. Dispos.* 52, 957-965.
- Rysz M, Schäfer AM, Paloumpis N, Kinzi J, Brecht K, Seibert I, Schmidlin S, In-Albon K, **Ricklin D**, Meyer zu Schwabedissen HE. 2024. Humanization of SLCO2B1 in Rats Increases rCYP3A1 Protein Expression but Not the Metabolism of Erlotinib to OSI-420. *J. Pharmacol. Exp. Ther.* 389, 87-95.
- Conti G, Bärenwaldt A, Rabbani S, Mühlethaler T, Sarcevic M, Jiang X, Schwardt O, **Ricklin D**, Pieters RJ, Läubli H, Ernst B. 2023. Tetra- and Hexavalent Siglec-8 Ligands Modulate Immune Cell Activation. *Angew. Chem. Int. Ed. Engl.* 62, e202314280.
- Golomingi M, Kohler J, Lamers C, Pouw RB, **Ricklin D**, Dobó J, Gál P, Pál G, Kiss B, Dopler A, Schmidt CQ, Hardy ET, Lam W, Schroeder V. 2023. Complement inhibition can decrease the haemostatic response in a microvascular bleeding model at multiple levels. *Front. Immunol.* 14, 1226832.
- Bechtler C, Barneoud-Rousset O, Pang L, Martin K, König KF, Hänggi P, Pearson N, **Ricklin D.** 2023. Optimized synthesis, polymer conjugation, and proof-of-concept studies of the gd-IgA1 epitope for antibody-scavenging therapies in IgA nephropathy. *Chem. Biol. Drug Des.* 102, 580-586.
- Rysz MA, Kinzi J, Schäfer AM, In-Albon K, Zürcher S, Schmidlin S, Seibert I, Schwardt O, **Ricklin D**, Meyer Zu Schwabedissen HE. 2023. Simultaneous quantification of atorvastatin, erlotinib and OSI-420 in rat serum and liver microsomes using a novel liquid chromatography-mass spectrometry method. *J. Pharm. Biomed. Anal.* 236, 115716.
- Lamers C, **Ricklin D**, Lambris JD. 2023. Complement-Targeted Therapeutics: An Emerging Field Enabled by Academic Drug Discovery, *Am. J. Hematol.* 98, S82-S89.
- Bechtler C, Koutsogiannaki S, Umnyakova E, Hamid A, Gautam A, Sarigiannis Y, Pouw RB, Lamers C, Rabbani S, Schmidt CQ, Lambris JD, **Ricklin D.** 2023. Complement-regulatory biomaterial coatings: Activity and selectivity profile of the factor H-binding peptide 5C6. *Acta Biomater.* 155, 2023, 123-138.
- Lamers C, Xue X, Smieško M, van Son H, Wagner B, Berger N, Sfyroera G, Gros P, Lambris JD*, **Ricklin D***. 2022. Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors. *Nat. Comm.* 13, 5519.
- Li B, Bechtler C, Jenny L, **Ricklin D**, Schroeder V. 2022. Exploring the function of factor XIII free B subunit: Interactions with complement factors and a novel approach to identify potential binding partners. *Res. Pract. Thromb. Haemost.* 6, e12766.
- Lamers C, Mastellos DC, **Ricklin D***, Lambris JD*. 2022. Compstatins: The dawn of clinical C3-targeted complement inhibition. *Trends Pharmacol. Sci.* 43, 629-640.
- Girardi B, Manna M, Van Klaveren S, Tomašić T, Jakopin Ž, Leffler H, Nilsson UJ, **Ricklin D**, Mravljak J, Schwardt O, Anderluh M. 2022. Selective Monovalent Galectin-8 Ligands Based on 3-Lactoylgalactoside. *ChemMedChem* 17, e202100514.
- Mastellos DC, **Ricklin D**, Sfyroera G, Sahu A. 2022. From discovery to approval: A brief history of the compstatin family of complement C3 inhibitors. *Clin. Immunol.* 235, 108785.
- Ricklin D**, Pouw RB. 2021. Complement & disease: out of the shadow into the spotlight. *Semin. Immunopathol.* 43, 755-756.
- Pouw RB, **Ricklin D.** 2021. Tipping the balance: intricate roles of the complement system in disease and therapy. *Semin. Immunopathol.* 43, 757-771.
- Schwardt O, Lamers C, Bechtler C, **Ricklin D.** 2021. Therapeutic Peptides as Emerging Options to Restore Misguided Host Defence and Homeostasis: From Teaching to Concept to Clinic. *Chimia* 75, 495-499.
- Zwarthoff SA, Widmer K, Kuipers A, Strasser J, Ruyken M, Aerts PC, de Haas CJC, Ugurlar D, den Boer MA, Vidarsson G, van Strijp JAG, Gros P, Parren PWHI, van Kessel KPM, Preiner J, Beurskens

- FJ, Schuurman J, **Ricklin D**, Rooijackers SHM. 2021. C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases. *Proc. Natl. Acad. Sci. U.S.A.* 118, e2102787118.
- Lamers C, Plüss CJ, **Ricklin D.** 2021. The Promiscuous Profile of Complement Receptor 3 in Ligand Binding, Immune Modulation, and Pathophysiology. *Front. Immunol.* 12, 662164.
- Dopler A, Stibitzky S, Hevey R, Mannes M, Höchsmann B, Schrezenmeier H, **Ricklin D**, Schmidt DQ. 2021. Deregulation of Factor H (FH) by Factor H-related protein 1 (FHR-1) depends on sialylation of host surfaces, *Front. Immunol.* 12, 615748.
- Hevey R, Pouw RB, Harris CL, **Ricklin D.** 2020. Sweet Turning Bitter: Carbohydrate Sensing of Complement in Host Defence and Disease, *Brit. J. Pharmacol.* 178, 2802-2822.
- Olcina MM, Kim RK, Balanis NG, Li CG, von Eyben R, Graeber TG, **Ricklin D**, Stucki M and Giaccia AJ. 2020. Intracellular C4BPA levels regulate NF- κ B dependent apoptosis. *iScience* 23, 101594.
- Kroezen BS, Conti G, Girardi B, Cramer J, Jiang X, Rabbani S, Muller J, Kokot M, Luisoni E, **Ricklin D**, Schwardt O, Ernst B. 2020. A Potent Mimetic of the Siglec-8 Ligand 6'-Sulfo-Sialyl Lewis^x, *ChemMedChem* 15, 1706-19.
- Hughes S, Gumas J, Lee R, Rumano M, Berger N, Gautam AK, Sfyroera G, Chan AL, Gnanaguru G, Connor KM, Kim BJ, Dunaief JL, **Ricklin D**, Hajishengallis G, Yancopoulos D, Reis ES, Mastellos DC, Lambris JD. 2020. Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates. *Clin. Immunol.* 214, 108391.
- Baas I, Delvasto-Núñez L, Ligthart P, Brouwer C, Folman C, Reis ES, **Ricklin D**, Lambris JD, Wouters D, de Haas M, Jongerius I, Zeerleder SS. 2020. Complement C3 inhibition by compstatin Cp40 prevents intra- and extravascular hemolysis of red blood cells. *Haematologica* 105, e57-e60.
- Mastellos DC, Blom AM, Connolly ES, Daha MR, Geisbrecht BV, Ghebrehiwet B, Gros P, Hajishengallis G, Holers VM, Huber-Lang M, Kinoshita T, Molines TE, Montgomery RA, Morgan BP, Nilsson B, Pio R, **Ricklin D**, Risitano AM, Taylor RP, Mantovani A, Ioannidis JPA, Lambris JD. 2019. 'Stealth' corporate innovation: an emerging threat for therapeutic drug development. *Nat. Immunol.* 20, 1409-1413.
- Ricklin D**, Mastellos DC, Lambris JD. Therapeutic targeting of the complement system. 2019. *Nat. Rev. Drug Discov.* doi: 10.1038/s41573-019-0055-y.
- Mastellos DC, **Ricklin D**, Lambris JD. 2019. Clinical promise of next-generation complement therapeutics. *Nat. Rev. Drug Discov.* 18, 707-729.
- Lombardi E, Matte A, Risitano AM, **Ricklin D**, Lambris JD, De Zanet D, Jokiranta S, Martinelli N, Scambi C, Salvagno G, Bisoffi Z, Colato C, Siciliano A, Bortolami O, Mazzuccato M, Zorzi F, de Marco L, De Franceschi L. 2019. Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease modulating molecule. *Haematologica* 104, 919-928.
- van Griensven M, **Ricklin D**, Denk S, Halbgebauer R, Braun CK, Schultze A, Hönes F, Koutsogiannaki S, Primikyri A, Reis E, Messerer D, Hafner S, Radermacher P, Biglarnia AR, Resuello RRG, Tuplano JV, Mayer B, Nilsson K, Nilsson B, Lambris JD, Huber-Lang M. 2019. Protective effects of the complement inhibitor compstatin Cp40 in hemorrhagic shock. *Shock* 51, 78-87.
- Harris CL, Pouw RB, Kavanagh D, Sun R, **Ricklin D.** 2018. Developments in anti-complement therapy; from disease to clinical trial. *Mol. Immunol.* 102, 89-119.
- Devaurs D, Papanastasiou M, Antunes DA, Abella JR, Moll M, **Ricklin D**, Lambris JD, Kavrakli LE. 2018. Native state of complement protein C3d analysed via hydrogen exchange and conformational sampling. *Int. J. Comput. Biol. Drug Des.* 11, 90-113.
- Ricklin D**, Mastellos DC, Reis ES, Lambris JD. 2018. The Renaissance of Complement Therapeutics. *Nat. Rev. Nephrol.* 14, 26-47.
- Reis ES, Mastellos DC, **Ricklin D**, Mantovani A, Lambris JD. 2018. Complement in cancer: untangling an intricate relationship. *Nat. Rev. Immunol.* 18, 5-18.
- Yuan X, Yang M, Chen X, Zhang X, Sukhadia S, Musolino N, Bao H, Chen T, Xu C, Wang Q, Santoro S, **Ricklin D**, Hu J, Lin R, Yang W, Li Z, Qin W, Zhao A, Scholler N, Coukos G. 2018. Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy. *Cancer Immunol. Immunother.* 67, 329-339.
- Blatt AZ, Saggiu G, Cortes C, Herbert AP, Kavanagh D, **Ricklin D**, Lambris JD, Ferreira VP. 2017. Factor H C-terminal domains are critical for regulation of platelet/granulocyte aggregate formation. *Front. Immunol.* 8, 1586.
- Wang H, Lambris JD*, **Ricklin D***. 2017. Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4. *Proc. Natl. Acad. Sci. U.S.A.* 114, 10948-10953.
- Hajishengallis G, Reis ES, Mastellos DC, **Ricklin D**, Lambris JD. 2017. Novel Mechanisms and Functions of Complement. *Nat. Immunol.* 18, 1288-1298.

41. **Ricklin D***, Barratt-Due A, Mollnes TE*. 2017. Complement in clinical medicine: Clinical trials, case reports and therapy monitoring. *Mol. Immunol.* 89, 10-21.
42. Xue X, Wu J, **Ricklin D**, Forneris F, Di Crescenzo P, Schmidt CQ, Granneman J, Sharp TH, Lambris JD, Gros P. 2017. Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses. *Nat. Struct. Mol. Biol.* 24, 643-651.
43. Papanastasiou M, Koutsogiannaki S, Sarigiannis Y, Geisbrecht BV, Lambris JD*, **Ricklin D***. 2017. Structural implications for the formation and function of the complement effector protein iC3b. *J. Immunol.* 198, 3326-3335.
44. Mastellos DC, Reis ES, **Ricklin D**, Smith RJ, Lambris JD. 2017. Complement C3-targeted therapy: replacing long-held assertions with evidence-based discovery. *Trends Immunol.* 38, 383-394.
45. Devaurs D, Antunes DA, Papanastasiou M, Moll M, **Ricklin D**, Lambris JD, Kavraki LE. 2017. Coarse-grained conformational sampling of protein structure improves the fit to experimental hydrogen-exchange data. *Front. Mol. Biosci.* 4, Article 13 (eCollection).
46. Harder MJ, Kuhn N, Schrezenmeier H, Höchsmann B, von Zabern I, Weinstock C, Simmet T, **Ricklin D**, Lambris JD, Skerra A, Anliker M, Schmidt CQ. 2017. Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. *Blood* 129, 970-980.
47. Primikyri A, Papanastasiou M, Sarigiannis Y, Koutsogiannaki S, Reis ES, Tuplano JV, Resuello RR, Nilsson B, Lambris JD*, **Ricklin D***. 2017. Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS. *J. Chromatogr. B* 1041-1042, 19-26.
48. **Ricklin D***, Lambris JD*. 2016. Preformed mediators of defense – gatekeepers enter the spotlight (Editorial). *Immunol. Rev.* 274, 5-8.
49. **Ricklin D**, Reis ES, Mastellos MC, Gros P, Lambris JD. 2016. Complement component C3: the "Swiss Army Knife" of Innate Immunity and Host Defense. *Immunol. Rev.* 274, 33-58.
50. Schmidt CQ, Lambris JD, **Ricklin D**. 2016. Protection of host cells by complement regulators. *Immunol. Rev.* 274, 152-171.
51. Lindorfer MA, Cook EM, Reis ES, **Ricklin D**, Risitano AM, Lambris JD, Taylor RP. 2016. Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia. *Clin. Immunol.* 171, 32-35.
52. Yuan X, Yang M, Chen X, Zhang X, Sukhadia S, Musolino N, Bao H, Chen T, Xu C, Wang Q, Santoro S, **Ricklin D**, Hu J, Lin R, Yang W, Li Z, Qin W, Zhao A. 2016. Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy. *Cancer Immunol. Immunother.* 66, 367-378.
53. Mastellos DC, Reis ES, Yancopoulou D, Hajishengallis G, **Ricklin D**, Lambris JD. 2016. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. *Immunobiology* 221, 1046-57.
54. **Ricklin D**, Reis ES, Lambris JD. 2016. Complement in disease: a defence system turning offensive. *Nat. Rev. Nephrol.* 12, 383-401.
55. **Ricklin D***, Lambris JD*. 2016. Complement therapeutics (Editorial). *Semin. Immunol.* 28, 205-7.
56. **Ricklin D***, Lambris JD*. 2016. New milestones ahead in complement-targeted therapy. *Semin. Immunol.* 28, 208-22.
57. Hajishengallis G, Hajishengallis E, Kajikawa T, Wang B, Yancopoulou D, **Ricklin D**, Lambris JD. 2016. Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. *Semin. Immunol.* 28, 285-91.
58. Forneris F, Wu J, Xue X, **Ricklin D**, Lin Z, Sfyroera G, Tzekou A, Volokhina E, Granneman JC, Hauhart R, Bertram P, Liszewski MK, Atkinson JP, Lambris JD, Gros P. 2016. Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode. *EMBO J.* 35, 1133-49.
59. Blatt AZ*, Saggu G*, Kulkarni KV, Cortes C, Thurman JM, **Ricklin D**, Lambris JD, Valenzuela JG, Ferreira VP. 2016. Properdin-mediated C5a production enhances stable binding of platelets to granulocytes in human whole blood. *J. Immunol.* 196, 4671-80.
60. **Ricklin D**, Lambris JD. 2016. Therapeutic control of complement activation at the level of the central component C3. *Immunobiology* 221, 740-6.
61. Schmidt CQ, Harder MJ, Nichols EM, Hebecker M, Anliker M, Höchsmann B, Simmet T, Csincsi ÁI, Uzonyi B, Pappworth IY, **Ricklin D**, Lambris JD, Schrezenmeier H, Józsi M, Marchbank KJ. 2016. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. *Immunobiology* 221, 503-11.

62. Maekawa T, Briones RA, Resuello RR, Tuplano JV, Hajishengallis E, Kajikawa T, Koutsogiannaki S, Garcia CA, **Ricklin D**, Lambris JD*, Hajishengallis G*. 2016. Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3. *J. Clin. Periodontol.* 43, 238-49.
63. Harder MJ, Anliker M, Höchsmann B, Simmet T, Huber-Lang M, Schrezenmeier H, **Ricklin D**, Lambris JD, Barlow PN, Schmidt CQ. 2016. Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation. *J. Immunol.* 196, 866-76.
64. Wang J, Wang L, Xiang Y, **Ricklin D**, Lambris JD, Chen G. 2016. Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40. *Clin. Immunol.* 162, 37-44.
65. Mastellos DC, **Ricklin D**, Hajishengallis E, Hajishengallis G, Lambris JD. 2016. Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention. *Mol. Oral Microbiol.* 31, 3-17.
66. Lin Z, Schmidt CQ, Koutsogiannaki S, Ricci P, Risitano AM, Lambris JD*, **Ricklin D***. 2015. Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. *Blood* 126, 891-894. *Highlighted as editorial in "This Week in Blood" (Roumenina, Blood 126, 882-883).*
67. Reis ES, Mastellos DC, Yancopoulou D, Risitano AM, **Ricklin D**, Lambris JD. 2015. Applying complement therapeutics to rare diseases. *Clin. Immunol.* 161, 225-240.
68. Georgoutsou-Spyridonos M, **Ricklin D**, Pratsinis H, Perivolioti E, Pirmettis I, Garcia BL, Geisbrecht BV, Foukas PG, Lambris JD, Mastellos DC, Sfyroera G. 2015. Attenuation of *S. aureus*-induced bacteremia by human mini-antibodies targeting the complement inhibitory protein Efb. *J. Immunol.* 195, 3946-58.
69. Hamad OA, Mitroulis I, Fromell K, Kozarcanin H, Chavakis T, **Ricklin D**, Lambris JD, Ekdahl KN, Nilsson B. 2015. Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18. *Thromb. Haemost.* 114, 1207-17.
70. Zhang Y, Shao D, **Ricklin D**, Hilkin BM, Nester CM, Lambris JD, Smith RJ. 2015. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. *Immunobiology* 220, 993-8.
71. **Ricklin D***, Sfyroera G*, Reis ES, Chen H, Wu EL, Kaznessis YN, Ekdahl KN, Nilsson B, Lambris JD. 2015. Rare loss-of-function mutation in complement component C3 provides insight into molecular and pathophysiological determinants of complement activity. *J. Immunol.* 194, 3305-16.
72. Mastellos DC, Yancopoulou D, Kokkinos P, Huber-Lang M, Hajishengallis G, Biglarnia AR, Lupu F, Nilsson B, Risitano AM, **Ricklin D**, Lambris JD. 2015. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. *Eur. J. Clin. Invest.* 45, 423-40.
73. Woehl JL, Stapels DAC, Garcia BL, Ramyar KX, Knightley A, Ruyken M, Syriga M, Sfyroera G, Weber AB, Zolkiewski M, **Ricklin D**, Lambris JD, Rooijackers SHM, Geisbrecht BV. 2014. The extracellular adherence protein from *Staphylococcus aureus* inhibits the classical and lectin pathways of complement by blocking formation of the C3 pro-convertase. *J. Immunol.* 193, 6161-71.
74. Rafail S, Kourtzelis I, Foukas PG, Markiewski MM, DeAngelis RA, Guariento M, **Ricklin D**, Grice EA, Lambris JD. 2015. Complement deficiency promotes cutaneous wound healing in mice. *J. Immunol.* 194, 1285-91.
75. Reis ES, DeAngelis RA, Chen H, Resuello RR, **Ricklin D***, Lambris JD*. 2015. Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. *Immunobiology* 220, 476-82.
76. Kourtzelis I, Ferreira A, Mitroulis I, **Ricklin D**, Bornstein SR, Waskow C, Lambris JD, Chavakis T. 2015. Complement inhibition in a xenogeneic model of interactions between human whole blood and porcine endothelium. *Horm. Metab. Res.* 47, 36-42.
77. Mastellos DC, **Ricklin D**, Yancopoulou D, Risitano AM, Lambris JD. 2014. Complement in paroxysmal nocturnal hemoglobinuria: Exploiting our current knowledge to improve the treatment landscape. *Exp. Rev. Hematol.* 7, 583-598.
78. Huang Y, Reis ES, Knerr PJ, van der Donk WA, **Ricklin D***, Lambris JD*. 2014. Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatin. *ChemMedChem* 9, 2223-6.
79. Maekawa T, Abe T, Hajishengallis E, Hosur KB, DeAngelis RA, **Ricklin D**, Lambris JD, Hajishengallis G. 2014. Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis. *J. Immunol.* 192, 6020-7.
80. **Ricklin D***, Risitano AM*, Huang Y, Reis ES, Chen H, Ricci P, Lin Z, Pascariello C, Raia M, Sica M, Del Vecchio L, Pane F, Lupu F, Notaro R, Resuello RRG, DeAngelis RA, Lambris JD. 2014. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal

- nocturnal hemoglobinuria. *Blood* 123, 2094-101. *Highlighted as editorial in "This Week in Blood" (Thurman J, Blood 123, 1975-1976).*
81. Klapper Y, Hamad OA, Teramura Y, Leneweit G, Nienhaus GU, **Ricklin D**, Lambris JD, Ekdahl KN, Nilsson B. 2013. Phospholipid vesicles mediate a non-proteolytic activation of complement component C3 that cannot be regulated by complement inhibitors. *Biomaterials* 35, 3688-96.
 82. **Ricklin D**, Cines DB. 2013. TMA: Beware of Complements. *Blood* 122, 1997-9.
 83. Oikonomopoulou K, DeAngelis RA, Chen H, Diamandis EP, Hollenberg MD, Lambris JD*, **Ricklin D***. 2013. Induction of complement C3a receptor responses by kallikrein-related peptidase 14. *J. Immunol.* 191, 3858-66.
 84. Schmidt CQ, Bai H, Lin Z, Risitano AM, Barlow PN, Lambris JD* and **Ricklin D***. 2013. Rational engineering of a novel complement regulator affords double targeting of host cells and controls innate immunity in disease condition. *J. Immunol.* 190, 5712-21.
 85. Kourtzelis I, Rafail S, DeAngelis RA, Foukas PG, Lambris JD* and **Ricklin D***. 2013. Inhibition of biomaterial-induced complement activation attenuates inflammatory host response to implantation. *FASEB J.* 27, 2768-76.
 86. Yang K, Dinasarapu AR, Reis ES, DeAngelis RA, **Ricklin D**, Subramaniam S, Lambris JD. 2013. CMAP: Complement Map Database. *Bioinformatics* 29, 1832-3.
 87. **Ricklin D**, Lambris JD. 2013. Complement in immune and inflammatory disorders: pathophysiological mechanisms. *J. Immunol.* 190, 3831-3838.
 88. **Ricklin D**, Lambris JD. 2013. Complement in immune and inflammatory disorders: therapeutic interventions. *J. Immunol.* 190, 3839-3847.
 89. Nilsson PH, Ekdahl KN, Magnusson PU, Qu H, Iwata H, **Ricklin D**, Hong J, Lambris JD*, Nilsson B*, Teramura Y*. 2013. Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating. *Biomaterials* 34, 985-994.
 90. Garcia BL, Summers BJ, Ramyar KX, Tzekou A, Lin Z, **Ricklin D**, Lambris JD, Laity JH, Geisbrecht BV. 2013. A structurally dynamic N-terminal helix is a key functional determinant in Staphylococcal Complement Inhibitor (SCIN) proteins. *J. Biol. Chem.* 288, 2870-2881.
 91. **Ricklin D**, Reis ES, Lambris JD. 2012. A sweet spot to regulate complement-mediated inflammation. *Nat. Med.* 18, 1340-1341.
 92. **Ricklin D**. 2012. Manipulating the mediator: manipulation of the alternative complement pathway C3 convertase in health, disease and therapy. *Immunobiology* 217, 1057-1066.
 93. DeAngelis RA, Reis ES, **Ricklin D**, Lambris JD. 2012. Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. *Immunobiology* 217:1097-1105.
 94. Lambris JD, Hajishengallis G, **Ricklin D**. 2012. The XXIV International Complement Workshop (ICW) on October 10-15, 2012. Preface. *Immunobiology* 217, 1025.
 95. Abe T, Hosur KB, Hajishengallis E, Reis ES, **Ricklin D**, Lambris JD, Hajishengallis G. 2012. Local complement-targeted intervention in periodontitis: proof-of-concept using a C5a receptor antagonist. *J. Immunol.* 189, 5442-8.
 96. **Ricklin D***, Qu H*, Bai H, Chen H, Reis ES, Maciejewski M, Tzekou A, DeAngelis RA, Resuello RRG, Lupu F, Barlow PN, Lambris JD. 2012. New analogues of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. *Immunobiology* 218, 496-505.
 97. Reis ES, Chen H, Sfyroera G, Monk PN, Köhl J, Lambris JD*, **D. Ricklin***. 2012. C5aR-dependent cell activation by physiological concentrations of C5adesArg: Insights from a novel label-free cellular assay. *J. Immunol.* 189, 4797-4805.
 98. **Ricklin D**, Lambris JD. 2013. Progress and Trends in Complement Therapeutics. *Adv. Exp. Med. Biol.* 734, 1-22.
 99. Yang K, DeAngelis RA, Reed JE, **Ricklin D**, Lambris JD. 2013. Complement in action: an analysis of patent trends from 1976 through 2011. *Adv. Exp. Med. Biol.* 734, 301-313.
 100. Garcia BL, Summers BJ, Lin Z, Ramyar KX, **Ricklin D**, Kamath DV, Fu ZQ, Lambris JD, Geisbrecht BV. 2012. Diversity in the C3b convertase contact residues and tertiary structures of the staphylococcal complement inhibitor (SCIN) protein family. *J. Biol. Chem.* 287, 628-640.
 101. Garcia BL, Ramyar KX, **Ricklin D**, Lambris JD, Geisbrecht BV. 2012. Advances in understanding the structure, function, and mechanism of the SCIN and Efb families of Staphylococcal immune evasion proteins. *Adv. Exp. Med. Biol.* 946, 113-133.
 102. Oikonomopoulou K, **Ricklin D**, Ward PA, Lambris JD. 2012. Interactions between coagulation and complement—their role in inflammation. *Semin. Immunopathol.* 34, 151-165.
 103. Ekdahl KN, Lambris JD, Elwing H, **Ricklin D**, Nilsson PH, Teramura Y, Nicholls IA, Nilsson B. 2011. Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies. *Adv. Drug Deliv. Rev.* 63, 1042-1050.

104. Knerr PJ*, Tzekou A*, **Ricklin D**, Qu H, Chen H, van der Donk WA*, Lambris JD*. 2011. Synthesis and activity of thioether-containing analogues of the complement inhibitor compstatin. *ACS Chem. Biol.* 6, 753-760.
105. Wu YQ, Qu H, Sfyroera G, Tzekou A, Kay BK, Nilsson N, Ekdahl KN, Lambris JD*, **Ricklin D***. 2011. Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. *J. Immunol.* 186, 4269-4277.
106. Forneris F, **Ricklin D**, Wu J, Tzekou A, Wallace RS, Lambris JD*, Gros P*. 2010. Structures of C3b in complex with factors B and D give insight into complement convertase formation. *Science* 330, 1816-1820.
107. Qu H*, Magotti P*, **Ricklin D**, Wu EL, Kourtzelis I, Wu YQ, Kaznessis YN, Lambris JD. 2011. Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. *Mol. Immunol.* 48, 481-489.
108. Hamad OA, Nilsson PH, Lasaosa M, **Ricklin D**, Lambris JD, Nilsson B, Ekdahl KN. 2010. Contribution of chondroitin sulfate A to the binding of complement proteins to activated platelets. *PLoS One* 5, e12889.
109. **Ricklin D***, Chen H*, Hammel M, Garcia BL, McWhorter WJ, Sfyroera G, Wu YQ, Tzekou A, Li S, Geisbrecht BV, Woods Jr VL, Lambris JD. 2010. Allosteric inhibition of complement function by a staphylococcal immune evasion protein. *Proc. Natl. Acad. Sci. U. S. A.* 107, 17621-17626.
110. **Ricklin D**, Hajishengallis G, Yang K, Lambris JD. 2010. Complement: a key system for immune surveillance and homeostasis. *Nat. Immunol.* 11, 785-797.
111. Garcia BL, Ramyar KX, Tzekou A, **Ricklin D**, McWhorter WJ, Lambris JD, Geisbrecht BV. 2010. Molecular basis for complement recognition and inhibition determined by crystallographic studies of the staphylococcal complement inhibitor (SCIN) bound to C3c and C3b. *J. Mol. Biol.* 402, 17-29.
112. Qu H, **Ricklin D**, Lambris JD. 2009. Recent developments in low molecular weight complement inhibitors. *Mol. Immunol.* 47, 185-195.
113. Stokmaier D, Khorev O, Cutting B, Born R, **Ricklin D**, Ernst TO, Boni F, Schwinger K, Gentner M, Wittwer M, Spreafico M, Vedani A, Rabbani S, Schwardt O, Ernst B. 2009. Design, synthesis and evaluation of monovalent ligands for the asialoglycoprotein receptor (ASGP-R). *Bioorg. Med. Chem.* 17, 7254-7264.
114. Magotti P, **Ricklin D**, Qu H, Wu YQ, Kaznessis YN, Lambris JD. 2009. Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin. *J. Mol. Recognit.* 22, 495-505.
115. **Ricklin D**, Tzekou A, Garcia BL, Hammel M, McWhorter WJ, Sfyroera G, Wu YQ, Holers VM, Herbert AP, Barlow PN, Geisbrecht BV*, Lambris JD*. 2009. A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family. *J. Immunol.* 183, 2565-2574.
116. Wu J, Wu YQ, **Ricklin D**, Janssen BJ, Lambris JD*, Gros P*. 2009. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. *Nat. Immunol.* 10, 728-733.
117. Rooijackers SH*, Wu J*, Ruyken M, van Domselaar R, Planken KL, Tzekou A, **Ricklin D**, Lambris JD, Janssen BJ, van Strijp JA, Gros P. 2009. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. *Nat. Immunol.* 10, 721-727.
118. **Ricklin D***, Petrou PS*, Zavali M, Raptis I, Kakabakos SE, Misiakos K, Lambris JD. 2009. Real-time label-free detection of complement activation products in human serum by white light reflectance spectroscopy. *Biosens. Bioelectron.* 24, 3359-3364.
119. Garcia BL, Tzekou A, Ramyar KX, McWhorter WJ, **Ricklin D**, Lambris JD, Geisbrecht BV. 2009. Crystallization of human complement component C3b in the presence of a staphylococcal complement-inhibitor protein (SCIN). *Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun.* 65, 482.
120. Knecht S, **Ricklin D**, Eberle AN, Ernst B. 2009. Oligohis-tags: mechanisms of binding to Ni²⁺-NTA surfaces. *J. Mol. Recognit.* 22, 270-279.
121. **Ricklin D**, Lambris JD. 2008. Compstatin: a complement inhibitor on its way to clinical application. *Adv. Exp. Med. Biol.* 632, 273-292.
122. **Ricklin D**, Ricklin-Lichtsteiner SK, Markiewski MM, Geisbrecht BV, Lambris JD. 2008. Cutting edge: members of the Staphylococcus aureus extracellular fibrinogen-binding protein family inhibit the interaction of C3d with complement receptor 2. *J. Immunol.* 181, 7463-7467.
123. **Ricklin D***, Haspel N*, Geisbrecht BV, Kavraki LE, Lambris JD. 2008. Electrostatic contributions drive the interaction between Staphylococcus aureus protein Efb-C and its complement target C3d. *Protein Sci.* 17, 1894-1906.
124. **Ricklin D***, Schuster MC*, Papp K, Molnar KS, Coales SJ, Hamuro Y, Sfyroera G, Chen H, Winters MS, Lambris JD. 2008. Dynamic structural changes during complement C3 activation analyzed by hydrogen/deuterium exchange mass spectrometry. *Mol. Immunol.* 45, 3142-3151.

125. Lambris JD, **Ricklin D**, Geisbrecht BV. 2008. Complement evasion by human pathogens. *Nat. Rev. Microbiol.* 6, 132-142.
126. **Ricklin D**, Lambris JD. 2007. Complement-targeted therapeutics. *Nat. Biotechnol.* 25, 1265-1275.
127. **Ricklin D**, Lambris JD. 2007. Exploring the complement interaction network using surface plasmon resonance. *Adv. Exp. Med. Biol.* 598, 260-278.
128. **Ricklin D***, Hammel M*, Sfyroera G*, Pyrpasopoulos S*, Ramyar KX, Pop M, Jin Z, Lambris JD, Geisbrecht BV. 2007. Characterization of Ehpf, a secreted complement inhibitory protein from *Staphylococcus aureus*. *J. Biol. Chem.* 282, 30051-30061.
129. Hammel M*, Sfyroera G*, **Ricklin D**, Magotti P, Lambris JD*, Geisbrecht JD*. 2007. A structural basis for complement inhibition by *Staphylococcus aureus*. *Nat. Immunol.* 8, 430-437.
130. Herfurth L, Ernst B, Wagner B, **Ricklin D**, Strasser DS, Magnani JL, Benie AJ, Peters T. 2005. Comparative epitope mapping with saturation transfer difference NMR of sialyl Lewis(a) compounds and derivatives bound to a monoclonal antibody. *J. Med. Chem.* 48, 6879.

* Shared first or senior authorship.